Health

Diabetes :: Celiac disease common in kids with type 1 diabetes

Earlier studies suggest that children with type 1 diabetes are more likely to have a subsequent diagnosis of celiac disease. However, research is sparse on the risk of subsequent type 1 diabetes in individuals with celiac disease. We sought to determine the risk of subsequent type 1 diabetes diagnosed before the age of 20 years in children and adolescents with celiac disease in a national, general population-based cohort – Jonas F. Ludvigsson, Department of Pediatrics, ?rebro University Hospital, ?rebro.

Health :: WHO sets up network to combat corruption in medicines procurement

Huge amounts of money – up to $50 billion – are spent every year on pharmaceutical products, a market so large that it is extremely vulnerable to corruption. Recent estimates have shown that as much as 25% of medicines which are procured can be lost to fraud, bribery and other corrupt practices.

Tuberculosis :: Pioneers in TB control from Africa and India receive awards for outstanding achievements

Two individuals who helped transform tuberculosis (TB) control in their home countries have become the first winners of a prestigious international health prize, to mark their contribution to improved TB control. The Stop TB Partnership Kochon Prize was inaugurated this year, and will be awarded for the first time, at the 37th Union World Conference on Lung Health, Palais des Congr?s, Paris.

Health :: Future of sexual and reproductive health at tipping point

The first-ever global study of sexual and reproductive health – to be published in the medical journal The Lancet starting this week – shows a picture of declining financial support, increased political interference and an overall reluctance to tackle threats to sexual and reproductive health.

Health :: Pharmion enrolled first patient into Vidaza Patient Registry

Pharmion Corporation (Nasdaq: PHRM) announced today the enrollment of the first patient in AVIDA(TM), a registry for patients treated with Vidaza(R) (azacitidine for injectable suspension). Vidaza was approved in May 2004 for the treatment of all five French-American-British (FAB) subtypes of myelodysplastic syndromes (MDS): refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia or thrombocytopenia or requiring transfusions; refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). Myelodysplastic syndromes are a serious and life-threatening group of diseases in which the bone marrow does not function normally, resulting in the production of malformed or immature blood cells.

HIV :: New way to fight HIV / AIDS

For years researchers have been trying to understand how a few HIV-infected patients naturally defeat a virus that otherwise overwhelms the immune system. Last year, a research team at the University of Rochester Medical Center confirmed that such patients, called long-term non-progressors, maintain higher than normal levels of the enzyme called APOBEC-3G (A3G) in their white blood cells, which function to stave off infections. Now, the same group has teamed up with a structural biologist to provide the first look at the A3G structure. Such information represents an early step toward the design of a new class of drugs that could afford to all the same natural protection enjoyed by few, according to a study published today in The Journal of Biological Chemistry.

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack